Articles from Epicrispr Biotechnologies
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has been named a Finalist Team in XPRIZE Healthspan FSHD Bonus Prize, earning a $250,000 Milestone Award for its work addressing facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy globally.
By Epicrispr Biotechnologies · Via Business Wire · May 12, 2025
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced five presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held May 15-17, 2025, in New Orleans, Louisiana. The presentations will highlight the company’s progress across key areas, including its lead epigenetic therapeutic candidate EPI-321, novel Cas effectors for epigenome engineering, and innovations in compact modular epigenetic activators.
By Epicrispr Biotechnologies · Via Business Wire · May 5, 2025
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced a partnership with Springbok Analytics to incorporate advanced, AI-driven muscle MRI imaging and analysis into its first-in-human clinical trial of EPI-321, a potential first-in-class treatment for facioscapulohumeral muscular dystrophy (FSHD).
By Epicrispr Biotechnologies · Via Business Wire · April 23, 2025
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EPI-321, a first-in-class epigenetic therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease.
By Epicrispr Biotechnologies · Via Business Wire · April 3, 2025
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has secured $68 million in the first close of its Series B financing. The proceeds will support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease.
By Epicrispr Biotechnologies · Via Business Wire · March 26, 2025

– Company’s non-cutting technology, engineered to be even more compact and deliverable, demonstrates synergistic gene reactivation in vitro –
By Epicrispr Biotechnologies · Via GlobeNewswire · October 22, 2024